What can the stock market teach gastroenterologists about the cost of inflammatory bowel disease? More than you might think.
A new study using tools from the world of equity investing shows that the cost volatility of IBD is several times greater than that of all gastrointestinal disorders combined. The study’s findings were presented at this year’s Crohn’s and Colitis Congress (abstract P009). The researchers concluded that conditions such as Crohn’s and ulcerative